Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · TERMINATED

GAP-486 (ZP-123)

Arrhythmia

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-12-10. Registry source

WATCH · WITHDRAWN

GARDASIL®9

Healthy

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Business Reasons

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Business Reasons

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-14. Registry source

WATCH · SUSPENDED

Garlic Oil Macerate

Healthy

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Results inconclusive

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Results inconclusive

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-03-20. Registry source

WATCH · TERMINATED

gemcitabine

Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT FDA Hold May 2007

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

FDA Hold May 2007

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-06-08. Registry source

WATCH · SUSPENDED

Gemcitabine

Pancreatic Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in Japan. h

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in Japan. h

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-11-01. Registry source

WATCH · TERMINATED

Gemcitabine

Uterine Cervical Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Problems of recruitment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Problems of recruitment

Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-17. Registry source

WATCH · TERMINATED

Gemcitabine

Carcinoma of Unknown Primary

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT recruitment goals met

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

recruitment goals met

Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2008-01-10. Registry source

WATCH · SUSPENDED

gemcitabine

Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung...

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.

Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · SUSPENDED

Gemcitabine

Resectable Intrahepatic Cholangiocarcinoma

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Other - evaluation of patients on first stage

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Other - evaluation of patients on first stage

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-04. Registry source

WATCH · SUSPENDED

Gemcitabine

Advanced Solid Tumor, Advanced Lymphoma

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-01. Registry source

WATCH · TERMINATED

Gemcitabine

Triple Negative Breast Neoplasms

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Business Reasons

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Business Reasons

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-14. Registry source

WATCH · TERMINATED

gemcitabine

Pancreatic Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2005-11-07. Registry source